Meglumine antimoniate (MA) is a pentavalent antimonial (Sb-V) drug used to
treat leishmaniasis. Despite the fact that Sb-V organic compounds have been
used in clinical practice for more than 50 years, information on their saf
ety during pregnancy is still scanty. This study was undertaken to evaluate
the embryo/fetotoxicity of MA in the rat. Wistar rats were treated subcuta
neously (s.c.) with MA (300 mg Sb-V/kg body wt/day) on days 6 through 15 of
pregnancy or with a higher dose (3 x 300 mg Sb-V/kg body wt) on day 11 onl
y, A control group treated with saline on days 6 through 15 and an untreate
d control group were evaluated as well. Cesarean sections were performed on
day 21. No maternal toxicity and no reduction of fetal weight were noted i
n the groups treated with MA. The repeated administration of MA (days 6 thr
ough 15), but not the: acute treatment (day 11), enhanced embryolethality.
Treatment with MA on days 6 through 15 also caused a higher incidence of an
atlas bone anomaly that occurs spontaneously at very low frequencies in ou
r rat strain. These findings indicated that repeated administration of MA w
as embryolethal and teratogenic in ruts. (C) 2001 Elsevier Science Inc. All
rights reserved.